Mastocytosis - Cause of anaphylactoid reactions;Mastozytose - Ursache anaphylaktoider reaktionen

Allergo Journal

Volumn 15, Issue 2, 2006, Pages 143-152

  Brockow, Knut ^a   Ring, Johannes ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anaphylaxis; Mastocytosis; Tryptase

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANAPEN; ANTIHISTAMINIC AGENT; ANTIRHEUMATIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CELESTAMINE; CROMOGLYCATE DISODIUM; DIMETINDENE; FASTJEKT; GLUCOCORTICOID; HYDROXYZINE; HYMENOPTERA VENOM; NONSTEROID ANTIINFLAMMATORY AGENT; POLYMYXIN B; PREDNISOLONE; PREDNISONE; PROTON PUMP INHIBITOR; PSORALEN; TRYPTASE; VITAMIN D;

ANAPHYLAXIS; BONE MARROW; BONE MARROW BIOPSY; CLINICAL FEATURE; DESENSITIZATION; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME BLOOD LEVEL; HUMAN; MASTOCYTOSIS; PAPULE; PATHOGENESIS; PHYSICAL EXAMINATION; PHYSICIAN; PROFESSIONAL KNOWLEDGE; PROGNOSIS; PUVA; REVIEW; SKIN EXAMINATION; URTICARIA PIGMENTOSA;

EID: 33645721635     PISSN: 09418849     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03361488     Document Type: Review

References (37)

1. British Thoracic Society, Scottish Intercollegiate 1. Akin C, Brockow K, Ambrosio C d', Kirshenbaum AS, Ma Y, Longley BJ, et al. Metcalfe DD. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003; 31: 686-92
2. Akin C, Fumo C, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103: 3222-5
3. Akin C, Metcalfe DD. Surrogate markers of disease in mastocytosis. Int Arch Allergy Immunol 2002; 127: 133-6
4. Akin C, Metcalfe DD. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 2004; 114: 13-9
5. Akin C, Schwartz LB, Kitoh T, Obayashi H, Worobec AS, Scott LM, Metcalfe DD. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology. Blood 2000; 96: 1267-73
6. Brockow K. Urticaria pigmentosa. Immunol Allergy Clin North Am 2004; 24: 287-316
7. Brockow K, Akin C, Huber M, Metcalfe DD. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol 2003; 48: 508-16
8. Brockow K, Akin C, Huber M, Metcalfe DD. IL-6 levels predict disease variant and extent of organ in-volvement in patients with mastocytosis. Clin Immunol 2005; 115: 216-23
9. Brockow K, Akin C, Huber M, Scott LM, Schwartz LB, Metcalfe DD. Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: correlation with dermal mast-cell numbers and mast-cell tryptase. J Allergy Clin Immunol 2002; 109: 82-8
10. Brockow K, Metcalfe DD. Mastocytosis. Curr Opin Allergy Clin Immunol 2001; 1: 449-54
11. n. Brockow K, Scott LM, Worobec AS, Kirshenbaum A, Akin C, Huber MM, Metcalfe DD. Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease. Arch Dermatol 2002; 138: 785-90
12. Caplan RM. The natural course of urticaria pigmentosa. Arch Dermatol 1963; 87: 146-57
13. Daley T, Metcalfe DD, Akin C. Association of the Q576R polymorphism in the interleukin-4 receptor alpha chain with indolent mastocytosis limited to the skin. Blood 2001; 98: 880-2
14. Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002; 81: 677-90
15. Florian S, Krauth MT, Simonitsch-Klupp I, Sperr WR, Fritsche-Polanz R, Sonneck K, Fodinger M, Agis H, Bohm A, Wimazal F, Horny HP, Valent P. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol 2005; 136: 273-80
16. Fricker M, Helbling A, Schwartz L, Müller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 1997; 100: 11-5
17. Hartmann K, Metcalfe DD. Pediatric mastocytosis. Hematol Oncol Clin North Am 2000; 14: 625-40
18. Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000; 14: 579-623
19. Kettelhut BV, Metcalfe DD. Pediatric mastocytosis. J Invest Dermatol 1991; 96: 155-85
20. Kirshenbaum A. Regulation of mast cell number and function. Hematol Oncol Clin North Am 2000; 14: 497-516
21. Ludolph-Hauser D, Schöpf P, Rueff F, Przybilla B. Okkulte kutane Mastozytose. Hautarzt 2001; 52: 390-3
22. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 77: 1033-79
23. Muller U, Helbling A, Hunziker T, Wuthrich B, Pecoud A, Gilardi S, Beretta E, Fasel J, Messerli W, Maurer P. Mastocytosis and atopy: a study of 33 patients with urticaria pigmentosa. Allergy 1990; 45: 597-603
24. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995; 92: 10560-4
25. Oude Elberink JN, Monchy JG de, Kors JW, Doormaal JJ van, Dubois AE. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997; 99: 153-4
26. Parker RI. Hematologic aspects of systemic mastocytosis. Hematol Oncol Clin North Am 2000; 14: 557-68
27. Pusl T, Kenngott S, Bartl R, Baur A, Ludolph-Hauser D, Juengst D. A case of systemic mastocytosis associated with severe osteoporosis and pathologic fractures. Eur J Intern Med 2004; 15: 537-9
28. Ring J. Angewandte Allergologie, 3. Aufl. München: Urban & Vogel Verlag, 2004
29. Ring J, Behrendt H. Anaphylaxis and anaphylactoid reactions. Classification and pathophysiology. Clin Rev Allergy Immunol 1999; 17: 387-99
30. Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001; 108: 1027-32
31. Schwartz LB, Irani AM. Serum tryptase and the laboratory diagnosis of systemic mastocytosis. Hematol Oncol Clin North Am 2000; 14: 641-57
32. Soter NA. Mastocytosis and the skin. Hematol Oncol Clin North Am 2000; 14: 537-55
33. Tefferi A, Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 2004; 11: 58-64
34. Valent P, Horny H, Li C, Longley B, Metcalfe D, Parawesch R, Benett JM. Mastocytosis. In: Jaffe E, Harris N, Stein H, Vardiman J, eds. World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissue. Lyon: IARC Press; 2001: 293-302
35. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone C, Nunez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW, Bennett JM. Diagnosic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603-25
36. Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol 2004; 114: 3-11
37. Worobec AS. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 2000; 14: 659-87